{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:09:40Z","timestamp":1784239780585,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFF0507403"],"award-info":[{"award-number":["2024YFF0507403"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejso.2026.111871","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:56:08Z","timestamp":1778579768000},"page":"111871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quality of life in patients with pseudomyxoma peritonei treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy and implications for ERAS-informed rehabilitation"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8179-1562","authenticated-orcid":false,"given":"Shu-Li","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6158-1557","authenticated-orcid":false,"given":"Yu-Run","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-6538","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejso.2026.111871_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejso.2022.08.023","article-title":"Clinical epidemiology of peritoneal metastases in China: the construction of professional peritoneal metastases treatment centers based on the prevalence rate","volume":"49","author":"Yang","year":"2023","journal-title":"Eur J Surg Oncol"},{"issue":"20","key":"10.1016\/j.ejso.2026.111871_bib2","first-page":"1527","article-title":"Chinese expert consensus on cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei","volume":"99","author":"Li","year":"2019","journal-title":"Natl Med J China (Peking)"},{"issue":"6","key":"10.1016\/j.ejso.2026.111871_bib3","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/jso.27842","article-title":"New insights in the management of pseudomyxoma peritonei","volume":"130","author":"Pastier","year":"2024","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111871_bib4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jss.2012.12.040","article-title":"Improved survival of patients with pseudomyxoma peritonei receiving intraperitoneal chemotherapy with cytoreductive surgery: a systematic review and meta-analysis","volume":"183","author":"McBride","year":"2013","journal-title":"J Surg Res"},{"issue":"41","key":"10.1016\/j.ejso.2026.111871_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005111","article-title":"Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional Colon cancer surgery","volume":"95","author":"Simkens","year":"2016","journal-title":"Medicine (Baltim)"},{"issue":"3","key":"10.1016\/j.ejso.2026.111871_bib9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s10880-022-09918-0","article-title":"Depression, anxiety, stress and distress following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results of a prospective cohort study","volume":"30","author":"Oswald","year":"2023","journal-title":"J Clin Psychol Med Settings"},{"issue":"4","key":"10.1016\/j.ejso.2026.111871_bib10","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1245\/s10434-017-6326-0","article-title":"Long-term quality of life after cytoreductive surgery and heated intraperitoneal chemotherapy for pseudomyxoma peritonei: a prospective longitudinal study","volume":"25","author":"Stearns","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2026.111871_bib12","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11136-012-0344-y","article-title":"ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research","volume":"22","author":"Reeve","year":"2013","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.ejso.2026.111871_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMp1611252","article-title":"Patient-reported outcomes\u2014harnessing patients' voices to improve clinical care","volume":"376","author":"Basch","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejso.2026.111871_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The EORTC QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.ejso.2026.111871_bib15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111871_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"issue":"12","key":"10.1016\/j.ejso.2026.111871_bib17","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.ejso.2014.08.477","article-title":"Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a systematic review","volume":"40","author":"Seretis","year":"2014","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2026.111871_bib18","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1245\/s10434-020-08379-9","article-title":"Systematic review of factors affecting quality of life after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"27","author":"Leimk\u00fchler","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111871_bib19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1245\/s10434-012-2579-9","article-title":"Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk","volume":"20","author":"Tsilimparis","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2026.111871_bib20","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ejso.2010.09.004","article-title":"Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei","volume":"36","author":"Alves","year":"2010","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2026.111871_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107045","article-title":"Health-related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin","volume":"49","author":"Kung","year":"2023","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2026.111871_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.suronc.2014.10.002","article-title":"Quality of life after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy for peritoneal carcinomatosis: a systematic review and meta-analysis","volume":"23","author":"Shan","year":"2014","journal-title":"Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111871_bib23","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1186\/s12885-021-08609-7","article-title":"Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials","volume":"21","author":"Gamper","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2026.111871_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types","volume":"188","author":"Musoro","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2026.111871_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejso.2004.09.011","article-title":"Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"31","author":"Schmidt","year":"2005","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2026.111871_bib26","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1684\/bdc.2010.1165","article-title":"Prospective study of quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using oxaliplatin for peritoneal carcinomatosis","volume":"97","author":"Lim","year":"2010","journal-title":"Bull Cancer"},{"issue":"5","key":"10.1016\/j.ejso.2026.111871_bib27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ejso.2013.11.019","article-title":"Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients","volume":"40","author":"Passot","year":"2014","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2026.111871_bib28","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ejso.2020.07.041","article-title":"Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): the ERAS\u00ae Society recommendations part I\u2014preoperative and intraoperative management","volume":"46","author":"H\u00fcbner","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.111871_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2021.713171","article-title":"Enhanced recovery after surgery for patients undergoing CRS+HIPEC: systematic review and meta-analysis","volume":"8","author":"Mao","year":"2021","journal-title":"Front Surg"},{"key":"10.1016\/j.ejso.2026.111871_bib30","article-title":"Implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy: a feasibility study","volume":"56","author":"Pandraklakis","year":"2024","journal-title":"Gynecol Oncol Rep"},{"issue":"3","key":"10.1016\/j.ejso.2026.111871_bib31","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jso.27931","article-title":"Implementation of a multidisciplinary enhanced recovery after surgery (ERAS) program for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"131","author":"Stockley","year":"2025","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.111871_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1515\/pp-2024-0033","article-title":"Implementation of an enhanced recovery after surgery (ERAS) program in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: study protocol for a prospective multicenter interventional trial (EPICH study)","volume":"10","author":"Robella","year":"2025","journal-title":"Pleura Peritoneum"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326004907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326004907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:46:00Z","timestamp":1784238360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326004907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0748798326004907"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111871","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of life in patients with pseudomyxoma peritonei treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy and implications for ERAS-informed rehabilitation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111871"}}